SEC Form SC 13G filed by Global Blood Therapeutics Inc.
$GBT
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2022 | Outperform → Mkt Perform | William Blair | |
| 8/8/2022 | $40.00 → $72.00 | Hold → Buy | Canaccord Genuity |
| 3/28/2022 | $138.00 → $71.00 | Outperform | Wedbush |
| 2/28/2022 | $28.00 → $31.00 | Equal-Weight | Morgan Stanley |
| 2/24/2022 | $92.00 → $86.00 | Outperform | Oppenheimer |
| 12/21/2021 | $56.00 → $53.00 | Outperform | SVB Leerink |
| 12/14/2021 | $54.00 → $56.00 | Outperform | SVB Leerink |
| 12/7/2021 | Market Perform → Outperform | William Blair |
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Month, is open to the public and will be live streamed on the SCD Therapeutics Conference website and the Facebook page of Sickle Cell Warriors, an SCD community organization. Admiral Rachel Levine, M.D., assistant secretary for health, U.S. Department of Health and Human Services (HHS), will provide remarks at the
NEW YORK, NY / ACCESSWIRE / August 27, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
-Reuters
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter. Global Blood Therapeutics collected $55.16 million in revenue during Q1, but reported earnings showed a $81.42 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the futur
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47 million. Global Blood Therapeutics collected $55.16 million in revenue during Q1, but reported earnings showed a $81.42 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings pe
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo
William Blair downgraded Global Blood Therapeutics from Outperform to Mkt Perform
Canaccord Genuity upgraded Global Blood Therapeutics from Hold to Buy and set a new price target of $72.00 from $40.00 previously
Wedbush resumed coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $71.00 from $138.00 previously
15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)